title: The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.
abstract: The relationship between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response (TR) of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients have been extensively investigated by many studies, but the results were inconsistent and inconclusive. The aim of this meta-analysis was to further explore the predictive value of the GSTP1 and GSTM1 polymorphisms by collecting currently available evidence. Relevant studies were searched in PubMed, Embase, and CNKI. Inclusion criteria were NSCLC patients receiving platinum-based treatment, evaluated GSTP1 A313G or GSTM1 null/present polymorphisms, and TR. Odds ratio (OR) with 95 % confidence interval (CI) was calculated to assess the strength of the associations. Subgroup analysis by race was also conducted to explore the source of heterogeneity. A total of nine studies including 961 NSCLC patients were qualified for analysis. We found that GSTM1 null/present but not GSTP1 A313G polymorphism was associated with platinum-based TR (for GSTM1, null vs present: OR = 1.77, 95% CI = 1.19-2.62). When subgroup analysis by race was done, both GSTP1 and GSTM1 polymorphisms were significantly associated with TR in East-Asian patients, but not in Caucasians. In addition, the heterogeneity disappeared in Asian and Caucasian patients when subgroup analysis by race was done. Our study suggested that the GSTP1 A313G and GSTM1 null/present polymorphisms could predict the treatment response of the platinum-based chemotherapy in NSCLC patients, especially in East-Asian patients.
authors.affiliation: Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, China, yangyl58@163.com.
authors.forename: Yanlong
authors.initials: Y
authors.lastname: Yang
authors.forename: Lei
authors.initials: L
authors.lastname: Xian
mesh_terms: D044466:Asian People / Q000235:genetics; D054316:Biomarkers, Pharmacological; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D020022:Genetic Predisposition to Disease; D051549:Glutathione S-Transferase pi / Q000235:genetics*; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D010984:Platinum / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide
chemical_list: D054316:Biomarkers, Pharmacological; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D010984:Platinum
references.citation: Mol Cell Biochem. 2001 Mar;219(1-2):51-6
references.pmid: 11354253
references.citation: Crit Rev Oncol Hematol. 2010 Sep;75(3):173-234
references.pmid: 20047843
references.citation: Cancer Treat Rev. 2009 Feb;35(1):18-31
references.pmid: 18771857
references.citation: J Thorac Oncol. 2006 Sep;1(7):679-83
references.pmid: 17409936
references.citation: CRC Crit Rev Biochem. 1988;23(3):283-337
references.pmid: 3069329
references.citation: Cancer. 2012 May 1;118(9):2466-75
references.pmid: 22031394
references.citation: Clin Lung Cancer. 2009 Mar;10(2):118-23
references.pmid: 19362955
references.citation: Chest. 2006 Oct;130(4):1211-9
references.pmid: 17035458
references.citation: J Thorac Oncol. 2009 Jul;4(7):891-910
references.pmid: 19433989
references.citation: Lung. 2012 Feb;190(1):91-8
references.pmid: 22109568
references.citation: Crit Rev Biochem Mol Biol. 1995;30(6):445-600
references.pmid: 8770536
references.citation: Cancer Chemother Pharmacol. 2010 Feb;65(3):437-46
references.pmid: 19568750
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: PLoS One. 2012;7(6):e38150
references.pmid: 22761669
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Swiss Med Wkly. 2011 Oct 19;141:w13275
references.pmid: 22009704
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Eur J Biochem. 1994 Sep 15;224(3):893-9
references.pmid: 7925413
references.citation: N Engl J Med. 2008 Sep 25;359(13):1367-80
references.pmid: 18815398
references.citation: PLoS One. 2012;7(11):e50587
references.pmid: 23189206
references.citation: Cancer Treat Rev. 2007 Feb;33(1):9-23
references.pmid: 17084534
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120